Epigenomics Files Third Module of PMA to FDA for Colon Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics today announced it has submitted the third of four modules to US regulators for possible approval of its Epi proColon blood-based colorectal cancer screening test.

The German molecular diagnostics company said it expects to submit the fourth and final module to the US Food and Drug Administration in the second half of this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.